The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis
- 1 March 2016
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 34 (13), 1540-1550
- https://doi.org/10.1016/j.vaccine.2016.02.024
Abstract
No abstract availableKeywords
Funding Information
- McGill University
- Pfizer
- GlaxoSmithKline
This publication has 48 references indexed in Scilit:
- Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transitionThe Lancet, 2015
- The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old—Taiwan's PPV vaccination programVaccine, 2015
- Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in AdultsThe New England Journal of Medicine, 2015
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA StatementJournal of Clinical Epidemiology, 2009
- Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska Native adultsVaccine, 2007
- Current methods of the U.S. Preventive Services Task Force: A review of the processAmerican Journal of Preventive Medicine, 2001
- Meta-analysis of Observational Studies in EpidemiologyA Proposal for ReportingJama-Journal Of The American Medical Association, 2000
- Bias in meta-analysis detected by a simple, graphical testBMJ, 1997
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- Pneumococcal Disease after Pneumococcal VaccinationThe New England Journal of Medicine, 1980